CMV Pneumonia

What is CMV Pneumonia?

CMV pneumonia is a lung infection caused by cytomegalovirus, a common virus in the herpes family. Most healthy people who get infected with CMV never know it because their immune system keeps the virus under control. However, when your immune system is weakened, CMV can reactivate and cause serious infections like pneumonia.

This condition most often affects people who have received organ transplants, those with HIV/AIDS, or anyone taking medications that suppress the immune system. CMV pneumonia develops when the virus inflames the lung tissue, making it hard to breathe properly. The virus can spread through body fluids including saliva, blood, urine, and breast milk.

CMV stays dormant in your body after the first infection and can reactivate years later if your immune defenses weaken. This is why people with compromised immunity need regular monitoring for CMV. Early detection through blood testing can help doctors intervene before the virus causes severe lung damage.

Cytomegalovirus (CMV) Antibodies, IgM, Quantitative

Detect CMV infection early for better treatment
Clarify unexplained symptoms like fatigue or fever
Verify your immune response to CMV accurately

^$65

Cytomegalovirus (CMV) Antibodies, IgG

Detect past CMV infections easily
Reveal your immune system's response
Clarify unexplained symptoms quickly

^$66

Symptoms

Shortness of breath that gets worse over time
Persistent dry cough that does not produce mucus
Fever above 100.4 degrees Fahrenheit
Fatigue and extreme weakness
Chest pain or tightness when breathing
Rapid breathing or increased respiratory rate
Low oxygen levels in the blood
Night sweats and chills

Some people may have mild symptoms at first that gradually worsen over several weeks. Others develop severe breathing problems quickly, especially if their immune system is significantly weakened. Anyone with immune suppression who develops respiratory symptoms should seek medical attention promptly.

Causes and risk factors

CMV pneumonia occurs when the cytomegalovirus reactivates in people with weakened immune systems. Organ transplant recipients face the highest risk because anti-rejection medications suppress immune function to prevent the body from attacking the new organ. People with HIV/AIDS are also highly susceptible, particularly when their CD4 cell count drops below 50 cells per microliter. Cancer patients receiving chemotherapy, bone marrow transplant recipients, and those taking long-term corticosteroids also have increased risk.

The virus spreads through close contact with infected body fluids, but healthy immune systems usually prevent any symptoms. Risk increases dramatically when immune function declines due to disease or medication. Age also plays a role, as older adults and premature infants have less robust immune responses. People who were never exposed to CMV before receiving an organ transplant face higher risk if they receive an organ from a CMV-positive donor.

How it's diagnosed

Diagnosing CMV pneumonia requires multiple tests because symptoms overlap with other lung infections. Doctors typically start with a chest X-ray or CT scan to look for inflammation patterns in the lungs. Blood tests can detect CMV antibodies, including IgG antibodies that indicate past exposure and IgM antibodies that suggest recent or active infection. However, blood tests alone cannot confirm CMV is causing pneumonia.

The most definitive diagnosis comes from examining lung tissue or fluid obtained through bronchoscopy, a procedure where doctors insert a thin tube into the lungs. Lab analysis looks for CMV DNA or the virus itself in these samples. Some labs also measure CMV viral load in the blood, which shows how actively the virus is replicating. Talk to your doctor about specialized testing if you have a weakened immune system and develop respiratory symptoms.

Treatment options

Antiviral medications such as ganciclovir or valganciclovir to fight the virus directly
Intravenous immunoglobulin therapy to boost immune response in severe cases
Oxygen therapy to maintain adequate blood oxygen levels
Adjusting immunosuppressive medications when possible to allow immune recovery
Hospital admission for monitoring and intensive treatment in severe cases
Preventive antiviral therapy for high-risk transplant and HIV patients
Regular follow-up with infectious disease specialists
Good nutrition to support immune function during recovery

Frequently asked questions

Organ transplant recipients face the highest risk, especially in the first few months after transplant when immunosuppression is strongest. People with HIV/AIDS who have very low CD4 counts, bone marrow transplant patients, and those receiving high-dose chemotherapy are also at significant risk. Anyone taking long-term immune-suppressing medications for autoimmune diseases may be vulnerable.

CMV pneumonia is extremely rare in people with healthy immune systems. While most adults have been exposed to CMV at some point, a functioning immune system keeps the virus dormant and prevents it from causing pneumonia. Healthy individuals who contract CMV typically have no symptoms or only mild flu-like illness.

IgM antibodies appear first during a new CMV infection and typically indicate recent or active viral activity. IgG antibodies develop later and remain in your blood for life, showing you were exposed to CMV in the past. High levels of both antibodies together may suggest an active infection or reactivation in people with weakened immunity.

CMV pneumonia is caused by a virus rather than bacteria, so antibiotics do not work against it. It develops more slowly than bacterial pneumonia and primarily affects people with compromised immune systems. Treatment requires specific antiviral medications like ganciclovir, whereas bacterial pneumonia typically responds to antibiotics.

High-risk patients can take preventive antiviral medications to reduce their chance of developing CMV pneumonia. Transplant centers often test donors and recipients for CMV and may give prophylactic antivirals for several months after transplant. People with HIV should maintain their antiretroviral therapy to keep their immune system strong enough to control CMV.

Treatment typically lasts three to six weeks depending on how severe the infection is and how well the immune system recovers. People with very weak immune systems may need longer courses of antiviral therapy or even maintenance treatment to prevent relapse. Doctors monitor viral load through blood tests to determine when treatment can safely stop.

While CMV itself can spread through close contact with body fluids, CMV pneumonia is not highly contagious to people with healthy immune systems. The virus requires direct contact with infected saliva, blood, urine, or other fluids to spread. Most adults have already been exposed to CMV, and those with normal immunity can control the virus easily.

Untreated CMV pneumonia can cause severe respiratory failure and death, especially in people with very weak immune systems. The virus can also spread to other organs including the eyes, liver, and digestive tract. Early diagnosis and treatment with antiviral medications significantly improve survival rates and reduce the risk of long-term complications.

Yes, people with ongoing immune suppression can experience CMV reactivation multiple times. The virus never completely leaves your body after the first infection, so it can cause problems again if your immune system weakens further. This is why transplant recipients and people with HIV often need long-term monitoring and sometimes preventive antiviral therapy.

Blood tests for CMV antibodies can show if you have been exposed to the virus and whether you might have an active infection. Cytomegalovirus IgG antibodies indicate past exposure, while IgM antibodies suggest recent infection or reactivation. Doctors may also order CMV viral load tests that measure how much virus is circulating in your blood to assess infection severity.